Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 40Pancreatic Neoplasms 17Breast Neoplasms 17Esophageal Neoplasms 14Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Triple Negative Breast Neoplasms 11Rectal Neoplasms 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Nasopharyngeal Carcinoma 5Leukemia, Myeloid, Acute 5Endometrial Neoplasms 5Recurrence 4NSCLC 4Mouth Neoplasms 4Colonic Neoplasms 4Lymphoma 3Glioma 3Cholangiocarcinoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2

Interventions

Injections 2Midazolam 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Malignancies × Drug Therapy × Clear all
NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡